China approves AstraZeneca's Tagrisso in combination with chemotherapy for advanced lung cancer in adults.

China approves AstraZeneca's Tagrisso in combination with chemotherapy for first-line treatment of advanced lung cancer in adults. The approval came after trials showed longer progression-free survival in patients receiving the Tagrisso-chemo combo (25.5 months) compared to Tagrisso alone (16.7 months). This marks the first approval of its kind for the drug in China.